Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com
SOURCE Caris Life Sciences
IRVING, Texas, Jan. 2, 2018 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that David D. Halbert, Chairman and Chief Executive Officer, and David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference
on Monday, January, 8 at 3:00 p.m. PST in San Francisco, Calif. Company leadership will discuss its two proprietary, precision medicine technology platforms, ADAPT Biotargeting System™ and Caris Molecular Intelligence®, in addition to taking questions from the audience.
About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation, and the world's leading immunotherapy diagnostic expert. Caris Molecular Intelligence®, the company's Comprehensive Genomic Profiling Plus (CGP+) molecular testing service, assesses DNA, RNA and proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal a molecular blueprint to guide more precise and personalized treatment decisions. The ADAPT Biotargeting System™, the company's revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.
The Ruth Group
Kirsten Thomas / Joanna Zimmerman
Tel: +1-508-280-6592 / +1-646-536-7006
©2017 PR Newswire. All Rights Reserved.